The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.
Mitsuo TeradaAki ItoYuichiro KikawaKei KoizumiYoichi NaitoTatsunori ShimoiMikiya IshiharaTakashi YamanakaYukinori OzakiFumikata HaraRikiya NakamuraMasaya HattoriMinoru MiyashitaNaoto KondoTetsuhiro YoshinamiMasahiro TakadaKoji MatsumotoKazukata NaruiShinsuke SasadaTakayuki IwamotoMitsuchika HosodaYuko TakanoTakaaki ObaHitomi SakaiAkari MurakamiToru HiguchiJunko TsuchidaYuko TanabeTomoko ShigechiEmi TokudaMichiko HaraoShinichiro KashiwagiJunichi MaseJunichiro WatanabeShigenori E NagaiChikako YamauchiYutaka YamamotoHiroji IwataShigehira SajiTatsuya ToyamaPublished in: Breast cancer (Tokyo, Japan) (2023)
The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer were updated to the 2022 edition through a process started in 2018. The updated guidelines consist of 12 background questions (BQs), 33 clinical questions (CQs), and 20 future research questions (FRQs). Multiple outcomes including efficacy and safety were selected in each CQ, and then quantitative and qualitative systematic reviews were conducted to determine the strength of evidence and strength of recommendation, which was finally determined through a voting process among designated committee members. Here, we describe eight selected CQs as important updates from the previous guidelines, including novel practice-changing updates, and recommendations based on evidence that has emerged specifically from Japanese clinical trials.